Several important findings have emerged from the STAMPEDE trial. For instance, the addition of abiraterone to standard hormone therapy significantly improved survival rates in men with advanced prostate cancer. The trial also showed that early use of docetaxel could extend life expectancy. These results have led to changes in clinical guidelines and practice, making these combinations part of the standard treatment for advanced prostate cancer.
